Search

Author/Creator Sharman, Jeff

1. Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab. Issue 6 (12th May 2021)

Authors:
Lyons, Roger M.; Shtivelband, Mikhail; Kingsley, Edwin; Moezi, Mehdi; Richards, Donald; Sharman, Jeff; Feng, Xiaoshu; Cannan, Megan; Fellague-Chebra, Rafik; Boyd, Thomas E.
Journal:
Leukemia & lymphoma
Issue:
Volume 62:Issue 6(2021)
Page Start:
1353
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Idelalisib immune-related toxicity is associated with improved treatment response. Issue 12 (15th October 2021)

Authors:
Wagner-Johnston, Nina D.; Sharman, Jeff; Furman, Richard R.; Salles, Gilles; Brown, Jennifer R.; Robak, Tadeusz; Gu, Lin; Xing, Guan; Chan, Rebecca J.; Rajakumaraswamy, Nishanthan; Gopal, Ajay K.
Journal:
Leukemia & lymphoma
Issue:
Volume 62:Issue 12(2021)
Page Start:
2915
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib. Issue 4 (21st March 2021)

Authors:
Barrientos, Jacqueline C.; Hillmen, Peter; Salles, Gilles; Sharman, Jeff; Stilgenbauer, Stephan; Gurtovaya, Oksana; Xing, Guan; Ruzicka, Bianca; Bhargava, Pankaj; Ghia, Paolo; Pagel, John M.
Journal:
Leukemia & lymphoma
Issue:
Volume 62:Issue 4(2021)
Page Start:
837
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Issue 5 (May 2019)

Authors:
Morschhauser, Franck; Flinn, Ian W; Advani, Ranjana; Sehn, Laurie H; Diefenbach, Catherine; Kolibaba, Kathryn; Press, Oliver W; Salles, Gilles; Tilly, Hervé; Chen, Andy I; Assouline, Sarit; Cheson, Bruce D; Dreyling, Martin; Hagenbeek, Anton; Zinzani, Pier Luigi; Jones, Surai; Cheng, Ji; Lu, Dan;...
Journal:
Lancet
Issue:
Volume 6:Issue 5(2019)
Page Start:
e254
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single‐agent ibrutinib in patients with chronic lymphocytic leukaemia. (10th February 2019)

Authors:
Wierda, William G.; Byrd, John C.; O'Brien, Susan; Coutre, Steven; Barr, Paul M.; Furman, Richard R.; Kipps, Thomas J.; Burger, Jan A.; Stevens, Don A.; Sharman, Jeff; Ghia, Paolo; Flinn, Ian W.; Zhou, Cathy; Ninomoto, Joi; James, Danelle F.; Tam, Constantine S.
Journal:
British journal of haematology
Issue:
Volume 186:Number 1(2019)
Page Start:
184
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗